Thymosin alpha-1 reduces infections 44%, boosts immune cells, and improves outcomes in severe pancreatitis
Meta-analysis of 5 RCTs (706 patients) shows thymosin alpha-1 in severe acute pancreatitis increased CD4+ T cells, improved CD4/CD8 ratio, reduced extrapancreatic infections by 44% (especially blood and abdominal), and lowered APACHE II scores.
Quick Facts
What This Study Found
↑CD4+ T cells (MD=4.53, p<0.00001). ↑CD4/CD8 ratio (MD=0.42, p<0.00001). ↓CRP (low-dose): -30 mg/L (p<0.00001). ↓Infections: RR 0.56 (p=0.0005). Blood: RR 0.60. Abdominal: RR 0.38. ↓APACHE II: -1.52 (p<0.0001). Hospital stay: NS. 5 RCTs, 706 patients.
Key Numbers
How They Did This
Meta-analysis of 5 RCTs from PubMed, Embase, WoS, Cochrane, CNKI. 706 SAP patients. Review Manager 5.3. Random/fixed effects. PROSPERO CRD42024570517.
Why This Research Matters
SAP has 20-40% mortality, largely from secondary infections due to immune suppression. Tα1's ability to restore immune function and prevent infections addresses a critical unmet need.
The Bigger Picture
Tα1 is one of the few peptide immunomodulators with proven efficacy in critical care. Its ability to reverse SAP immune suppression and prevent lethal infections positions it as a standard of care candidate for severe pancreatitis.
What This Study Doesn't Tell Us
Only 5 RCTs available. Mostly Chinese studies. High-dose Tα1 did not reduce CRP (dose-response paradox). Hospital stay not reduced. Lung infection reduction NS.
Questions This Raises
- ?What is the optimal Tα1 dose for SAP?
- ?Should Tα1 be routine in ICU SAP management?
- ?Why did higher doses show less anti-inflammatory effect?
Trust & Context
- Key Stat:
- 44% fewer infections Thymosin alpha-1 reduced extrapancreatic infections by 44% in severe acute pancreatitis by restoring CD4+ T cell balance—a life-saving immune intervention
- Evidence Grade:
- Meta-analysis of 5 RCTs with 706 patients. Moderate evidence quality.
- Study Age:
- Published in 2025.
- Original Title:
- Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.
- Published In:
- Frontiers in immunology, 16, 1571456 (2025)
- Authors:
- Tian, Yong, Yao, Jiaqi, Ma, Yihan, Zhang, Pengcheng, Zhou, Xiaofang, Xie, Wenjie, Tang, Wenfu
- Database ID:
- RPEP-13810
Evidence Hierarchy
Frequently Asked Questions
What is thymosin alpha-1 used for in critical care?
Tα1 is an immune-boosting peptide that restores immune function in critically ill patients whose immune systems are suppressed. In severe pancreatitis, it increased protective immune cells (CD4+ T cells) and reduced dangerous secondary infections by 44%—especially bloodstream and abdominal infections.
Does thymosin alpha-1 help pancreatitis patients survive?
It helps by preventing the infections that kill pancreatitis patients. While it did not reduce hospital stay in this analysis, it significantly reduced infections (44% less) and improved disease severity scores. Blood infections dropped 40% and abdominal infections 62%—potentially life-saving in severe cases.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13810APA
Tian, Yong; Yao, Jiaqi; Ma, Yihan; Zhang, Pengcheng; Zhou, Xiaofang; Xie, Wenjie; Tang, Wenfu. (2025). Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.. Frontiers in immunology, 16, 1571456. https://doi.org/10.3389/fimmu.2025.1571456
MLA
Tian, Yong, et al. "Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.." Frontiers in immunology, 2025. https://doi.org/10.3389/fimmu.2025.1571456
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha 1 alleviates inflammation and prevents infect..." RPEP-13810. Retrieved from https://rethinkpeptides.com/research/tian-2025-thymosin-alpha-1-alleviates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.